je.st
news
Home
› Alexion's Soliris (eculizumab) Receives Orphan Drug Designation For The Treatment Of Neuromyelitis Optica (NMO)
Alexion's Soliris (eculizumab) Receives Orphan Drug Designation For The Treatment Of Neuromyelitis Optica (NMO)
2013-06-27 18:50:00| drugdiscoveryonline News Articles
Alexion Pharmaceuticals, Inc. recently announced that Soliris (eculizumab), the company’s first-in-class terminal complement inhibitor, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder
Tags: treatment
drug
receives
designation
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||